Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

ClinicalTrials.gov ID: NCT06914908

Public ClinicalTrials.gov record NCT06914908. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207). The study duration will be up to approximately 148 weeks per participant, including 144 weeks of treatment period and 4 weeks of follow-up.

Study identification

NCT ID
NCT06914908
Recruitment status
Enrolling by invitation
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sanofi
Industry
Enrollment
71 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 12, 2025 (Actual)
Primary completion
Jan 29, 2031 (Estimated)
Completion
Jan 29, 2031 (Estimated)
Last update posted
Oct 13, 2026

2025 – 2031

United States locations

U.S. sites
9
U.S. states
5
U.S. cities
9
Facility City State ZIP Site status
Orso Health- Site Number : 8400005 La Jolla California 92037 —
Capital Allergy & Respiratory Disease Center- Site Number : 8400003 Roseville California 95661 —
Treasure Valley Medical Research- Site Number : 8400002 Boise Idaho 83706 —
Essential Medical Research- Site Number : 8400020 Tulsa Oklahoma 74137 —
Pharmaceutical Research & Consulting- Site Number : 8400004 Dallas Texas 75231 —
The University of Texas Health Science Center- Site Number : 8400017 Houston Texas 77030 —
ENT Associates of Texas - McKinney- Site Number : 8400014 McKinney Texas 75070 —
Alamo ENT Associates- Site Number : 8400001 San Antonio Texas 78258 —
Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008 Norfolk Virginia 23510 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06914908, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 13, 2026 · Synced Oct 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06914908 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →